Provider education and point-of-care antibody testing benefit HCV patients

April 12, 2022

2 minutes of reading

Disclosures: Cunningham does not report relevant financial disclosures. Please refer to the study for relevant financial disclosures of all other authors.

We were unable to process your request. Please try again later. If you continue to experience this issue, please contact customerservice@slackinc.com.

A series of interventions improved testing, linkage to care and treatment initiation in patients with hepatitis C, according to a study published in The Lancet Gastroenterology and Hepatology.

Provider education and point-of-care antibody testing benefit HCV patients 83 cunningham headshotDr. Evan B. Cunningham

“The advent of direct-acting antiviral therapy (DAA) for the treatment of HCV has been one of the greatest clinical advances in decades, allowing for optimism that HCV could be eliminated globally.” Evan B. Cunningham, Doctor, associate professor in the viral hepatitis clinical research program at the Kirby Institute in Australia, he told Healio. “Since DAAs have become commonplace, considerable research has been done to optimize HCV models of care; however, there was no systematic review to bring everything together. This review sought to highlight those interventions that could be most effective in advancing the drive towards HCV elimination.”

Spread the love

What do you think?